R
Robert J. Kreitman
Researcher at Laboratory of Molecular Biology
Publications - 235
Citations - 13762
Robert J. Kreitman is an academic researcher from Laboratory of Molecular Biology. The author has contributed to research in topics: Immunotoxin & Pseudomonas exotoxin. The author has an hindex of 62, co-authored 225 publications receiving 12766 citations. Previous affiliations of Robert J. Kreitman include Medical University of South Carolina & Emory University.
Papers
More filters
Journal ArticleDOI
Efficacy of the Anti-CD22 Recombinant Immunotoxin BL22 in Chemotherapy-Resistant Hairy-Cell Leukemia
Robert J. Kreitman,Wyndham H. Wilson,Karen Bergeron,Miranda Raggio,Maryalice Stetler-Stevenson,David J. FitzGerald,Ira Pastan +6 more
TL;DR: BL22 can induce complete remissions in patients with hairy-cell leukemia that is resistant to treatment with purine analogues, including cladribine.
Journal ArticleDOI
Immunotoxin Therapy of Cancer
TL;DR: Results from clinical trials indicate that recombinant immunotoxins and similar agents that are designed to combine antibody selectivity with toxin cell-killing potency will be useful additions to cancer therapy.
Journal ArticleDOI
Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies.
Robert J. Kreitman,Wyndham H. Wilson,Jeffrey D. White,Maryalice Stetler-Stevenson,Elaine S. Jaffe,Steven L. Giardina,Thomas A. Waldmann,Ira Pastan +7 more
TL;DR: LMB-2 has clinical activity in CD25(+) hematologic malignancies and is relatively nonimmunogenic, the first recombinant immunotoxin to induce major responses in cancer.
Journal ArticleDOI
Immunotoxin Treatment of Cancer
TL;DR: The most potent immunotoxins are made from bacterial and plant toxins as discussed by the authors, which are composed of an antibody fragment linked to a toxin, and the immunotoxin binds to a surface antigen on a cancer cell, enters the cell by endocytosis, and kills it.
Journal ArticleDOI
Phase I Study of SS1P, a Recombinant Anti-Mesothelin Immunotoxin Given as a Bolus I.V. Infusion to Patients with Mesothelin-Expressing Mesothelioma, Ovarian, and Pancreatic Cancers
Raffit Hassan,Susie Bullock,Ahalya Premkumar,Robert J. Kreitman,Hedy L. Kindler,Mark C. Willingham,Ira Pastan +6 more
TL;DR: SS1P is well tolerated with pleuritis as the DLT at the highest dose level and Phase II clinical trials of SS1P are being planned for malignant mesothelioma and other mesothelin-expressing malignancies.